Dr. Milind Desai discusses the design and results of the VALOR-HCM trial, which demonstrated that mavacamten reduced the need for septal reduction therapy at 16 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Dr. Milind Desai discusses the design and results of the VALOR-HCM trial, which demonstrated that mavacamten reduced the need for septal reduction therapy at 16 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
